1. Home
  2. FOFO vs NEUP Comparison

FOFO vs NEUP Comparison

Compare FOFO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

FOFO

Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

N/A

Current Price

$1.76

Market Cap

15.8M

Sector

N/A

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$2.55

Market Cap

14.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FOFO
NEUP
Founded
2017
1996
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
14.9M
IPO Year
2025
2002

Fundamental Metrics

Financial Performance
Metric
FOFO
NEUP
Price
$1.76
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.1K
★ 32.8K
Earning Date
12-04-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,174,165.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.09
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.58
$2.54
52 Week High
$14.93
$5.53

Technical Indicators

Market Signals
Indicator
FOFO
NEUP
Relative Strength Index (RSI) 41.13 16.20
Support Level $1.76 N/A
Resistance Level $1.97 $4.15
Average True Range (ATR) 0.10 0.14
MACD 0.00 -0.04
Stochastic Oscillator 41.86 2.11

Price Performance

Historical Comparison
FOFO
NEUP

About FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares

Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Share on Social Networks: